Abstracts tagged "Eosinophilic Fasciitis (Shulman’s Disease)"

Abstract Number: 1055 • 2019 ACR/ARP Annual Meeting
Proteomic and Transcriptomic Analysis of Human Eosinophilic Fasciitis Fibroblasts
Benjamin Chaigne¹, Claire Fernandez ², Morgane le Gall ², Philippe Chafey ², Benjamin Saintpierre ², Virginie Salnot ², Francois Guillonneau ², Claire Le Jeunne ³ and Luc Mouthon ⁴, ¹Cochin University Hospital, Paris, France, ²Cochin Institute, Paris, France, ³Paris Descartes University, Cochin Hospital, Internal Medicine department, Paris, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Eosinophilic fasciitis (EF) is a rare scleroderma-like disorder with less than 200 cases reported. Due to the rarity of the disease, data regarding its…
Abstract Number: 267 • 2017 ACR/ARHP Annual Meeting
Musculoskeletal Ultrasound As a Diagnostic Tool for Eosinophilic Fasciitis and Correlation with MRI Findings
Florentina Berianu¹, Neha Narula² and Andy Abril¹, ¹Rheumatology, Mayo Clinic Florida, Jacksonville, FL, ²Division of Rheumatology, Mayo Clinic, Jacksonville, FL
Background/Purpose: Eosinophilic fasciitis (EF) presents with pain and induration of the skin. Currently the clinical diagnosis is based on typical physical findings along with MRI…
Abstract Number: 1168 • 2017 ACR/ARHP Annual Meeting
Eosinophilic Fasciitis: Baseline Retrospective Evaluation of Clinical Characteristics and Prognosis in a Cohort of 83 Patients
Robert L. Mango¹, Kubra Bugdayli², Cynthia S. Crowson³, Margot S. Peters⁴, Lisa A. Drage⁵, Julia S. Lehman⁴ and Vaidehi Chowdhary⁶, ¹Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ²Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Pathology and Dermatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ⁵Dermatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ⁶Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Eosinophilic fasciitis (EF) is a rare disease and there have been few published series that include clinical, pathological and serological data. These studies have…
Abstract Number: 1729 • 2017 ACR/ARHP Annual Meeting
Increased Serum Levels of Micro-RNA 30d and Micro-RNA 423-5p in 2 Independent Cohorts of Patients with Morphea
Jorre S. Mertens^1,2, Wiola Marut¹, Cornelis P.J. Bekker¹, Elke M.G.J. de Jong³ and Timothy R.D.J. Radstake^1,4, ¹Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Dermatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Radboud University Medical Center, Nijmegen, Netherlands, ⁴Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose : Morphea, also known as localized scleroderma, encompasses a group of idiopathic sclerotic skin diseases. MicroRNAs (miRNAs) are a large family of highly conserved…
Abstract Number: 111 • 2017 Pediatric Rheumatology Symposium
Eosinophilic Fasciitis in Children: Clinical Course and Response to Treatment from Two Large Academic Centers
Suhas Ganguli¹, Meiqian Ma², Christine Lauren³, Maria Garzon³, Cassyanne L. Aguiar⁴, Andrew Eichenfield⁵, Amy Starr⁶, Lisa F. Imundo^7,8, B. Anne Eberhard⁹ and Joyce Hui-Yuen¹⁰, ¹Pediatrics, Cohen Children's Medical Center of New York, Lake Success, NY, ²Pediatric Rheumatology, Cohen Children's Medical Center of New York, Lake Success, NY, ³Division of Pediatric Dermatology, Columbia University Medical Center, New York, NY, ⁴Pediatric Rheumatology, Children's Hospital of The King's Daughters, Norfolk, VA, ⁵Columbia University Medical Center, New York, NY, ⁶Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ⁷Pediatrics, Columbia University Medical Center, New York, NY, ⁸Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, ⁹Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁰Cohen Children's Medical Center of New York, Lake Success, NY
Background/Purpose: Eosinophilic fasciitis (EF) is a rare connective tissue disease characterized by a progressive inflammatory thickening of skin and soft tissues. The diagnosis is based…
Abstract Number: 1882 • 2016 ACR/ARHP Annual Meeting
Predictors of Response to Methotrexate in Patients with Eosinophilic Fasciitis (Shulman’s Disease)
Walter A. Sifuentes-Giraldo¹, Dolors Grados Canovas², Marina De Los Riscos Alvarez³, María Pascual Pastor⁴, Pablo Moreno Fresneda⁵, Estibaliz Loza⁶, María J. García Yébenes⁶, Alejandro Olivé², Patricia Carreira Delgado³, Francisco J. Narvaez Garcia⁴, Rosario García-Vicuña⁷ and Antonio Zea Mendoza¹, ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ³Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁶Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Eosinophilic fasciitis (EF) is a rare scleroderma-like disorder described in 1974 by Shulman. It is characterized by the acute onset of edema and induration…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].